IntelGenx, a leading drug-delivery company, has recently announced a research grant agreement with Karolinska University Hospital in Sweden. The company has already begun the manufacturing process of active and placebo films for an upcoming 18-month clinical study. The study aims to investigate the effectiveness of IntelGenx’s Montelukast VersaFilm for the treatment of Parkinson’s Disease.
Under this research collaboration, the clinical study will be conducted at Karolinska University Hospital, with Per Svenningsson, a renowned professor of clinical neuroscience, leading as the principal investigator. Dr. Svenningsson has previously conducted a clinical study utilizing the tablet form of Montelukast for Parkinson’s Disease treatment. He will sponsor this study through a substantial grant provided by the Swedish Research Council, the country’s largest governmental research funding body.
Upon completion of the study, IntelGenx will have the option to acquire the intellectual property rights and study data for a predetermined low five-digit amount. This valuable data will enable IntelGenx to further develop its Montelukast VersaFilm program for Parkinson’s Disease treatment.